옵션 체인은 다양한 행사가격과 만기일에 대한 Alvotech의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Alvotech에 대한 시장 심리를 평가합니다..

Alvotech (NASDAQ:ALVO) 주식, 옵션 체인

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">traded lower</a> on Tuesday. The EV maker is investing <a target="_blank" href="https://rivian.com/newsroom/article/rivian-to-bring-more-jobs-to-central-illinois-with-supplier-park" rel="noreferrer noopener">heavily in its operations in Normal, Illinois,</a> with the development of a new supplier park near its electric vehicle manufacturing facility.
Governor JB Pritzker and Rivian said that the company is <a target="_blank" href="https://gov.illinois.gov/news/press-release.31247.html#:~:text=NORMAL%20%2D%20Governor%20JB%20Pritzker%20and,nearly%20100%20new%20direct%20jobs" rel="noreferrer noopener">investing nearly $120 million to build</a> a 1.2 million-square-foot facility that will host component suppliers near its existing EV factory.
The move is expected to create nearly 100 new jobs directly at Rivian while drawing several additional suppliers to the region.
The project is part of Rivian's broader push to streamline its production process and deepen relationships with suppliers as it scales up operations.
Also Read: <a href="https://www.benzinga.com/tech/25/04/45113606/li-autos-next-evs-to-feature-cleaner-cabin-materials" target="_blank" rel="noreferrer noopener">Li Auto's Next EVs To Feature Cleaner Cabin Materials</a>
The supplier park will bring several of Rivian's key partners closer to the assembly line producing the R1 and upcoming R2 models, enabling faster, more coordinated delivery of materials and parts for its electric vehicles. Some suppliers will also conduct light manufacturing and part assembly on-site.
Rivian staff at the new supplier park will be responsible for organizing and preparing parts for assembly before they're moved to the primary manufacturing site.
To streamline transport and reduce surface traffic, an underground tunnel is being built to link the new park directly with the main production facility.
The project is supported by a $16 million incentive package from the State of Illinois. This includes a $5 million REV Illinois tax credit spread over 20 years, with the remainder coming in the form of capital grants.
Under the terms of the agreement, Rivian is obligated to create at least 93 full-time jobs and invest nearly $120 million in the development.
Construction of the supplier park is already underway, with completion targeted for 2026.
Adjacent to the supplier park, Rivian is already working on a 1.1 million square foot expansion of its primary facility. Production of the R2 is expected to begin in 2026.
Rivian currently produces its entire vehicle lineup at the Normal plant, including the R1T pickup, R1S SUV, the Amazon Electric Delivery Van (EDV), and the new Rivian Commercial Van now available to fleets of all sizes.
Price Action: RIVN shares traded lower by 1.11% at $13.40 in premarket at last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges" target="_blank" rel="noreferrer noopener">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a></li>
</ul>
Photo courtesy: Michael Berlfein via Shutterstock

News

Tech

General

RIVN

What's Going On With EV Maker Rivian Stock On Tuesday?

<a href="https://zoox.com/journal/2025-april-safety-recall-report/" title="https://zoox.com/journal/2025-april-safety-recall-report/">https://zoox.com/journal/2025-april-safety-recall-report/</a>

AMZN

'Zoox Issuing Voluntary Software Recall' - Zoox

Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares are trading lower by 1.7% to $53.15 Tuesday afternoon. The company will report its first-quarter earnings after Tuesday's market close, with analysts expecting a loss of 27 cents per share on revenue of $248.13 million. 
What To Know: Tuesday&#8217;s earnings report follows the Monday <a href="https://investors.tempus.com/news-releases/news-release-details/tempus-announces-notetaker-its-ai-powered-clinical-assistant">launch</a> of Notetaker, an AI clinical assistant that streamlines psychiatric documentation by ambiently recording sessions and generating notes for electronic health records.
The tool, available via Tempus Hub, enhances the company's mental health platform with features like multilingual transcription, pharmacogenomic insights, and HIPAA-compliant data storage. 
Tempus also recently deepened its <a href="https://www.benzinga.com/news/contracts/25/04/44960263/tempus-ai-stock-is-ripping-higher-wednesday-whats-fueling-the-move">strategic collaboration</a> with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology, under a $200 million agreement aimed at improving cancer therapeutics using Tempus' de-identified data.
In the fourth-quarter, Tempus reported $200.68 million in revenue—<a href="https://www.benzinga.com/news/earnings/25/02/43927560/tempus-ai-q4-earnings-revenue-miss-eps-beat-strong-guidance-shares-move-lower">up 35.8% year-over-year</a>—and a narrower-than-expected loss of $0.18 per share. The company ended the quarter with $940 million in remaining contract value and forecasts strong 2025 growth, aiming for $1.24 billion in revenue and positive adjusted EBITDA. 
Retail investor interest in Tempus has also increased in part due to notable <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43131818/whats-going-on-with-tempus-ai-shares-wednesday">options purchases</a> by former House Speaker Nancy Pelosi earlier this year.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/05/45227387/bessent-signals-imminent-trade-deals-dismisses-recession-fears-as-stocks-rebound">Bessent Signals Imminent Trade Deals, Dismisses Recession Fears As Stocks Rebound</a>
<h2 class="wp-block-heading">How To Buy TEM Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tempus AI&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TEM has a 52-week high of $91.45 and a 52-week low of $22.89.

Tempus AI (TEM) Stock Lower Ahead Of Q1 Earnings Report, Notetaker AI Debut

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) with a Outperform and lowers the price target from $45 to $43.

Price Target

Analyst Ratings

RNST

Keefe, Bruyette & Woods Maintains Outperform on Renasant, Lowers Price Target to $43

The TRUMP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) meme coin is down 22% over the past seven days, 16 days ahead of a gala <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45201052/trump-meme-coin-draws-attention-as-crypto-focused-dinners-projected-to-draw-millions">dinner for some token holders.</a>
What Happened: Despite the drop, on-chain data shows large holders moving tokens off exchanges, potentially a sign of longer-term positioning.
Blockchain <a href="https://x.com/lookonchain/status/1919689926482002275">data</a> from Lookonchain showed two newly created wallets withdrawing a total of 2.39 million TRUMP tokens, valued at around $28 million, from Binance. 
One of these wallets belongs to &#8216;MemeCore_ORG&#8217;, now sitting on a $2.8 million unrealized loss after their recent buys.
SpotOnChain <a href="https://x.com/spotonchain/status/1919688370281930808">shows</a> 1 million TRUMP coins, worth $10.84 million, withdrawn from Binance, signaling strong buy-side interest.
These withdrawals reflect a growing interest in becoming a top TRUMP holder, with the top 220 wallets eligible for the dinner and added perks reserved for the top 25. 
The token <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45201052/trump-meme-coin-draws-attention-as-crypto-focused-dinners-projected-to-draw-millions">generated over $324 million in trading fees</a>, with roughly 80% of the supply linked to Trump-affiliated wallets.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45201052/trump-meme-coin-draws-attention-as-crypto-focused-dinners-projected-to-draw-millions">Trump Meme Coin Draws Attention As Crypto-Focused Dinners Projected To Draw Millions</a>
What's Next: Anonymous trader Optimus is watching for scalp or swing long setups around the $8.20–$8.35 range, though a small bounce could form near previous highs at $8.75. 
Despite that, he's not fundamentally bullish and plans to exit longs quickly while continuing to favor short positions.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> levels for more take profit zones and potential small scalp longs for mini bounces Main level of interest for potential swing long is: $8.20 &#8211; $8.35, which may get front-run by a first strong reaction around the previous highs around $8.75 The only problem for longs… <a href="https://t.co/QTTIztWVAo">pic.twitter.com/QTTIztWVAo</a>
&mdash; Optimus (sunrunning) (@OptimusVibee) <a href="https://twitter.com/OptimusVibee/status/1919722186417299962?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader HASANXBT <a href="https://x.com/hasan_xbt/status/1919715432652558675">flagged</a> weakness after $TRUMP failed to reclaim supply zones. He sees downside toward the quarterly open at $10, with a break below opening clean short setups below $9.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/25/05/45187462/trump-denies-personal-profit-from-memecoin-venture-i-havent-even-looked">Trump Denies Personal Profit From Memecoin Venture: &#8216;I Haven&#8217;t Even Looked&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TRUMP

Trump Meme Coin Down 22% In 7 Days: What Is Going On?

Waldencast PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is scheduled to report its first-quarter results on May 13, after the market close.
The company is likely to miss margin and earnings expectations, according to Telsey Advisory Group.
The Waldencast Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5888c53977f9dd0001877a22/dana-telsey">Analyst Dana Telsey</a> maintained an Outperform rating and price of $5.
The Waldencast Thesis: The company could report in-line sales, but adjusted EBITDA of $8.2 million, missing current consensus of $10.3 million, due to margin of 12.0% coming in below expectations of 15.1%, Telsey said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"Within the topline, we look for 14% YoY growth at Obagi and a 13% YoY decline at Milk," she added.
Revenue growth was projected to be flat year-on-year due to "challenging prior year compare and retail partner inventory adjustments," the analyst stated.
Waldencast expects revenue growth to gain momentum as the year progresses, "driven by its innovation pipeline and continued distribution expansion, including the launch of Milk Makeup in Ulta Beauty stores in 1Q25," she wrote.
Waldencast is likely to have relatively less exposure to tariffs than its peers, Telsey further stated.
WALD Price Action: Shares of Waldencast had tanked by 2.55% to $2.65 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/insights/earnings/25/04/45017717/examining-the-future-leggett-platts-earnings-outlook"> </a> • <a href="https://www.benzinga.com/insights/earnings/25/04/45017717/examining-the-future-leggett-platts-earnings-outlook">Retailers Target Billions In Unused FSA/HSA Funds With Wellness And Beauty Push</a>
Photo: Dmytro Buianskyi via Shutterstock

Analyst Color

Previews

Reiteration

WALD

Waldencast Q1 Preview: Beauty Brand Glow Dims On Soft Margins, Flat Sales

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains DigitalBridge Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) with a Market Perform and lowers the price target from $13.5 to $10.5.

DBRG

Keefe, Bruyette & Woods Maintains Market Perform on DigitalBridge Gr, Lowers Price Target to $10.5

NVDA

ServiceNow And NVIDIA Announce Expansion Of Partnership To Fuel New Class Of Intelligent AI Agents Across The Enterprise

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Outperform and raises the price target from $114 to $118.

Keefe, Bruyette & Woods Maintains Outperform on Axis Capital Holdings, Raises Price Target to $118

<h3>Gainers</h3>
<ul>
<li>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) shares moved upwards by 41.3% to $6.28 during Tuesday's regular session. The company's market cap stands at $713.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) stock moved upwards by 31.22% to $3.63. The company's market cap stands at $475.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock rose 29.99% to $0.49. The market value of their outstanding shares is at $141.5 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) stock rose 22.84% to $8.41. The company's market cap stands at $2.3 billion. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares moved upwards by 19.59% to $0.8. The company's market cap stands at $6.8 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) shares increased by 18.77% to $3.55. The company's market cap stands at $88.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares fell 30.4% to $1.03 during Tuesday's regular session. The market value of their outstanding shares is at $18.1 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares declined by 26.21% to $0.98. The market value of their outstanding shares is at $1.8 million. </li>
<li>First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) stock decreased by 24.24% to $14.1. The market value of their outstanding shares is at $855.8 million. As per the press release, Q1 earnings came out today. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) stock fell 14.29% to $1.14. The market value of their outstanding shares is at $231.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock decreased by 13.95% to $0.86. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares declined by 12.69% to $2.96. The company's market cap stands at $12.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EVGO

FWRG

JFBR

LOBO

LVWR

NWTN

TDUP

TOPW

UCAR

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares rose 125.8% to $209.7 during Tuesday's regular session. The market value of their outstanding shares is at $2.7 billion. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 32.66% to $1.87. The company's market cap stands at $25.7 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 28.27% to $1.56. The company's market cap stands at $182.8 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock moved upwards by 26.68% to $2.22. The company's market cap stands at $93.8 million. The company's, Q1 earnings came out today. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 20.02% to $0.36. The market value of their outstanding shares is at $4.9 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 18.37% to $0.76. The market value of their outstanding shares is at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 67.2% to $0.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 44.74% to $0.21. The company's market cap stands at $3.8 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock decreased by 31.53% to $9.54. The company's market cap stands at $225.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares fell 21.24% to $3.88. The company's market cap stands at $204.4 million. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) shares declined by 21.15% to $10.7. The company's market cap stands at $913.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares fell 18.75% to $27.01. The company's market cap stands at $824.4 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CCLD

CYCC

HSTM

NCNA

SNDX

SXTC

TCMD

TLSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Babcock &amp; Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWSN#NYSE">BWSN</a>) stock rose 44.9% to $11.65 during Tuesday's regular session. </li>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock moved upwards by 32.92% to $2.18. The company's market cap stands at $28.3 million. </li>
<li>Advent Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) stock moved upwards by 28.01% to $3.61. The market value of their outstanding shares is at $9.5 million. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) stock increased by 26.9% to $8.49. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares moved upwards by 24.7% to $4.77. The company's market cap stands at $36.1 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares rose 22.21% to $1.65. The market value of their outstanding shares is at $199.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock fell 35.7% to $6.65 during Tuesday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock declined by 35.57% to $4.99. The company's market cap stands at $7.6 million. </li>
<li>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) stock fell 21.94% to $4.39. The company's market cap stands at $372.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) shares decreased by 19.99% to $125.02. The market value of their outstanding shares is at $958.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) stock declined by 15.3% to $2.62. The company's market cap stands at $37.2 million. </li>
<li>TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) shares declined by 14.92% to $3.65. The company's market cap stands at $108.4 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWNB

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

BWSN

ENGS

GPUS

HTCO

JELD

ONEG

RAIN

WLFC

ZCAR

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock rose 176.7% to $1.76 during Tuesday's regular session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) stock rose 106.88% to $1.31. The market value of their outstanding shares is at $4.1 million. </li>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares rose 37.96% to $13.38. The company's market cap stands at $4.7 billion. </li>
<li>Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) stock moved upwards by 34.51% to $42.3. The market value of their outstanding shares is at $813.3 million. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) shares rose 28.8% to $0.74. The market value of their outstanding shares is at $10.7 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) stock rose 26.32% to $7.87. The market value of their outstanding shares is at $13.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ichor Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) stock fell 22.9% to $16.08 during Tuesday's regular session. The company's market cap stands at $546.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) shares declined by 14.57% to $27.99. The company's market cap stands at $2.5 billion. The company's, Q1 earnings came out today. </li>
<li>Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) shares fell 14.4% to $9.16. The company's market cap stands at $676.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 13.62% to $45.32. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares declined by 13.19% to $107.45. The market value of their outstanding shares is at $253.5 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) stock fell 12.97% to $9.37. The market value of their outstanding shares is at $188.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CISO

DOCN

FARO

FOXO

ICHR

LSCC

MRIN

PLTR

PONY

SAIH

TBCH

WEAV

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Macro Economic Events

Macro Notification

Econ #s

Economics

USA 10-Year Note Auction 4.342% Vs 4.435% Prior

RGC Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGCO#NASDAQ">RGCO</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that RGC Resources will report an earnings per share (EPS) of $0.68.
The market awaits RGC Resources's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 0.28% drop in the share price on the subsequent day.
Here's a look at RGC Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.50</td>
<td>-0.01</td>
<td>0.07</td>
<td>0.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.51</td>
<td>0.01</td>
<td>0.02</td>
<td>0.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746551093_0.png" alt="eps graph" />
<h3>RGC Resources Share Price Analysis</h3>
Shares of RGC Resources were trading at $21.0 as of May 05. Over the last 52-week period, shares are up 3.06%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/RGCO/earnings">To track all earnings releases for RGC Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

RGCO

Earnings Preview For RGC Resources

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) with a Market Perform and raises the price target from $38 to $40.

Keefe, Bruyette & Woods Maintains Market Perform on American Homes 4 Rent, Raises Price Target to $40

MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate MaxCyte to report an earnings per share (EPS) of $-0.10.
Anticipation surrounds MaxCyte's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 8.36% drop in the share price the next day.
Here's a look at MaxCyte's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.13</td>
<td>-0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-11.0%</td>
<td>-8.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746551083_0.png" alt="eps graph" />
<h3>Tracking MaxCyte's Stock Performance</h3>
Shares of MaxCyte were trading at $2.67 as of May 05. Over the last 52-week period, shares are down 41.59%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on MaxCyte</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MaxCyte.
Analysts have given MaxCyte a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $9.0, indicating a potential 237.08% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of CryoPort, Maravai LifeSciences and Pacific Biosciences, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for CryoPort, with an average 1-year price target of $10.8, suggesting a potential 304.49% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $4.62, suggesting a potential 73.03% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Pacific Biosciences, with an average 1-year price target of $2.25, suggesting a potential 15.73% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for CryoPort, Maravai LifeSciences and Pacific Biosciences, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MaxCyte</td>
<td>Buy</td>
<td>-44.51%</td>
<td>$6.41M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>CryoPort</td>
<td>Buy</td>
<td>3.97%</td>
<td>$27.28M</td>
<td>-5.49%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>-23.92%</td>
<td>$18.96M</td>
<td>-7.80%</td>
</tr>
<tr>
<td>Pacific Biosciences</td>
<td>Outperform</td>
<td>-32.79%</td>
<td>$10.06M</td>
<td>0.49%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MaxCyte ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity. Overall, MaxCyte's performance is weaker compared to its peers in all key metrics analyzed.
<h3>All You Need to Know About MaxCyte</h3>
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
<h3>Key Indicators: MaxCyte's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, MaxCyte faced challenges, resulting in a decline of approximately -44.51% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -121.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): MaxCyte's ROE stands out, surpassing industry averages. With an impressive ROE of -5.05%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MaxCyte's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.34%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<a href="https://www.benzinga.com/quote/MXCT/earnings">To track all earnings releases for MaxCyte visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MXCT

A Look at MaxCyte's Upcoming Earnings Report

Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Valneva to report an earnings per share (EPS) of $-0.20.
Anticipation surrounds Valneva's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.32 in the last quarter, leading to a 1.1% drop in the share price on the following day.
Here's a look at Valneva's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.29</td>
<td>-0.30</td>
<td>0.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.54</td>
<td>-0.15</td>
<td>-0.37</td>
<td>0.89</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746551057_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Valneva were trading at $6.6562 as of May 05. Over the last 52-week period, shares are down 10.08%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/VALN/earnings">To track all earnings releases for Valneva visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VALN

Insights Ahead: Valneva's Quarterly Earnings

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Liberty Latin America will report an earnings per share (EPS) of $-0.12.
The announcement from Liberty Latin America is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.90, leading to a 5.17% drop in the share price on the subsequent day.
Here's a look at Liberty Latin America's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>-0.02</td>
<td>-0.08</td>
<td>-0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.9</td>
<td>-2.22</td>
<td>-0.22</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-21.0%</td>
<td>-9.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746551043_0.png" alt="eps graph" />
<h3>Market Performance of Liberty Latin America's Stock</h3>
Shares of Liberty Latin America were trading at $5.3 as of May 05. Over the last 52-week period, shares are down 37.44%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LILAK/earnings">To track all earnings releases for Liberty Latin America visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LILAK

An Overview of Liberty Latin America's Earnings

DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect DXP Enterprises to report an earnings per share (EPS) of $1.20.
The market awaits DXP Enterprises's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.49 in the last quarter, leading to a 0.31% increase in the share price on the following day.
Here's a look at DXP Enterprises's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.89</td>
<td>0.95</td>
<td>0.80</td>
<td>0.71</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.38</td>
<td>1.43</td>
<td>1.02</td>
<td>0.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>21.0%</td>
<td>-4.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746551019_0.png" alt="eps graph" />
<h3>Tracking DXP Enterprises's Stock Performance</h3>
Shares of DXP Enterprises were trading at $91.29 as of May 05. Over the last 52-week period, shares are up 64.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about DXP Enterprises</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding DXP Enterprises.
The consensus rating for DXP Enterprises is Outperform, derived from 1 analyst ratings. An average one-year price target of $95.0 implies a potential 4.06% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Xometry, Distribution Solns Gr and Dnow, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Xometry, with an average 1-year price target of $33.71, suggesting a potential 63.07% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Distribution Solns Gr, with an average 1-year price target of $44.0, suggesting a potential 51.8% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dnow, with an average 1-year price target of $19.0, suggesting a potential 79.19% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for Xometry, Distribution Solns Gr and Dnow are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXP Enterprises</td>
<td>Outperform</td>
<td>15.69%</td>
<td>$148.49M</td>
<td>5.17%</td>
</tr>
<tr>
<td>Xometry</td>
<td>Outperform</td>
<td>15.92%</td>
<td>$59.02M</td>
<td>-3.14%</td>
</tr>
<tr>
<td>Distribution Solns Gr</td>
<td>Outperform</td>
<td>14.89%</td>
<td>$163.98M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Dnow</td>
<td>Buy</td>
<td>2.88%</td>
<td>$133M</td>
<td>2.06%</td>
</tr>
</tbody>
</table>

Key Takeaway:
DXP Enterprises ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, DXP Enterprises is at the bottom compared to its peers.
<h3>All You Need to Know About DXP Enterprises</h3>
DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil &amp; Gas, Food &amp; Beverage, Water &amp; Wastewater, Chemical, Transportation, Aerospace &amp; Others.
<h3>DXP Enterprises: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: DXP Enterprises's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 15.69%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.53%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): DXP Enterprises's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 5.17%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.65%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.6, DXP Enterprises adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/DXPE/earnings">To track all earnings releases for DXP Enterprises visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXPE

A Glimpse of DXP Enterprises's Earnings Potential

Health Care

Press Releases

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech Reports Record Results for 2024 and Provides Business Update

Management

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Comments

Alvotech

Alvotech (ALVO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌